Araris will use its linker technology to generate multi-warhead ADCs for “undisclosed targets” provided by Chugai.

TORONTO, ON / ACCESSWIRE / January 7, 2025 / ProteinQure, a leader in computational peptide design, is proud to announce the addition of two distinguished leaders to its team. Dr. Dave Garman has been ...

TORONTO, ON / ACCESSWIRE / / ProteinQure, a leader in computational peptide design, is proud to announce the addition of two ...

CBX-12 is under clinical development by Cybrexa and currently in Phase II for Fallopian Tube Cancer. According to GlobalData, Phase II drugs for Fallopian Tube Cancer have a 41% phase transition ...